Bkemv (eculizumab-aeeb)
(eculizumab-aeeb)Amgen Inc
Usage: BKEMV is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody positive. Not for Shiga toxin E. coli related HUS.